Jose Baselga
Overview
Explore the profile of Jose Baselga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
394
Citations
63547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell M, et al.
Clin Cancer Res
. 2024 Aug;
30(16):3641.
PMID: 39143886
No abstract available.
2.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J, et al.
J Clin Oncol
. 2023 Feb;
41(6):1162-1171.
PMID: 36791474
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated...
3.
Pascual T, Oliveira M, Villagrasa P, Ortega V, Pare L, Bermejo B, et al.
NPJ Breast Cancer
. 2021 Nov;
7(1):145.
PMID: 34824288
Eribulin prolongs overall survival in patients with pre-treated advanced breast cancer. However, no biomarker exists to prospectively select patients who will benefit the most from this drug. SOLTI-1007-NeoEribulin is a...
4.
Gomez Tejeda Zanudo J, Mao P, Alcon C, Kowalski K, Johnson G, Xu G, et al.
Cancer Res
. 2021 Jul;
81(17):4603-4617.
PMID: 34257082
Durable control of invasive solid tumors necessitates identifying therapeutic resistance mechanisms and effective drug combinations. In this work, we used a network-based mathematical model to identify sensitivity regulators and drug...
5.
Smyth L, Reichel J, Tang J, Patel J, Meng F, Selcuklu D, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250397
Purpose: Cell-free DNA (cfDNA) analysis offers a noninvasive means to access the tumor genome. Despite limited sensitivity of broad-panel sequencing for detecting low-frequency mutations in cfDNA, it may enable more...
6.
Smyth L, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, et al.
NPJ Breast Cancer
. 2021 Apr;
7(1):44.
PMID: 33863913
Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which...
7.
Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, et al.
Br J Cancer
. 2021 Apr;
125(1):38-47.
PMID: 33828257
Background: We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Methods: Patients received 1...
8.
Moreno-Aspitia A, Holmes E, Jackisch C, de Azambuja E, Boyle F, Hillman D, et al.
Eur J Cancer
. 2021 Mar;
148:287-296.
PMID: 33765513
Aim: To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients And Methods: 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy...
9.
Bolton K, Ptashkin R, Gao T, Braunstein L, Devlin S, Kelly D, et al.
Nat Genet
. 2020 Oct;
52(11):1219-1226.
PMID: 33106634
Acquired mutations are pervasive across normal tissues. However, understanding of the processes that drive transformation of certain clones to cancer is limited. Here we study this phenomenon in the context...
10.
Subbiah V, Gervais R, Riely G, Hollebecque A, Blay J, Felip E, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914022
Purpose: To study whether V600 mutations in non-small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib...